Dermatitis
Amgen and Kyowa Kirin Provide Top-Line Results From Rocatinlimab Phase 3 IGNITE Study in Atopic Dermatitits
Amgen
PR-03-25-NI-03Mar 10, 2025
Drug Development
Nektar Therapeutics Receives Fast Track Designation for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
PR-02-25-NI-07Feb 10, 2025
Licensing
LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate
LEO Pharma
PR-M04-20-NI-023Apr 15, 2020
Phase III
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib for Moderate to Severe Atopic Dermatitis
Eli Lilly and Company
PR-M09-19-NI-001Sep 03, 2019
Pfizer Announces Positive Top-Line Results from Phase 3 Study in Patients with Moderate to Severe Atopic Dermatitis
Pfizer
PR-M05-19-NI-055May 20, 2019
Clinical Trials
AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for the Treatment of Pediatric Atopic Dermatitis
AOBiome Therapeutics, Inc.
PR-M03-19-NI-022Mar 08, 2019
Positive Trial
Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
Regeneron
PR-M05-18-NI-072May 18, 2018